Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study
REPOS
1 other identifier
interventional
140
1 country
1
Brief Summary
Polycystic Ovary Syndrome (PCOS) is very common, affecting approximately 5% of women of reproductive age, and impacts not only on quality of life, but also has long-term health consequences for many sufferers, such as increased risks of developing Type II diabetes, cardiovascular disease and cancer of the womb. The symptoms that may occur such as irregular periods; lots of body hair; thinning hair on scalp, obesity and infertility, can also lead to poor self-esteem. Whilst treatments can help fertility, other treatments to correct the other symptoms are less successful. Alternative methods to regulate periods would be helpful, especially ones which avoid the long-term use of steroids in patients who may already be overweight. Reflexology is poorly represented in scientific papers, with nothing published regarding reflexology and its effect upon PCOS. However patients who use reflexology report more regular periods, thicker hair on scalp and greater wellbeing. Therefore we aim to investigate the effect of reflexology on:
- 1.The menstruation cycle (normal being every 21-35 days).
- 2.Imbalances in hormone, insulin and blood sugar levels associated with PCOS.
- 3.Other problems associated with PCOS such as thinning hair on scalp, excessive body hair, and obesity.
- 4.Quality of life. Government and NHS agendas agree that if there's evidence of an effective complimentary therapy the NHS should provide it. Therefore the results may have an influence on the care pathways of patients with PCOS towards a more holistic, patient centred and empowered approach. It is also non invasive and liable to result in higher patient satisfaction regarding their treatment. This research may also inform policy makers so that complementary medicine provision is provided on a wider basis within the NHS, which at the moment is dictated by the individual Trust's budget allocation. However this research could save money overall as in America, the yearly cost of treating PCOS is $4.36 billion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Dec 2012
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 2, 2008
CompletedFirst Posted
Study publicly available on registry
September 3, 2008
CompletedStudy Start
First participant enrolled
December 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedDecember 4, 2012
December 1, 2012
11 months
September 2, 2008
December 3, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To identify the most appropriate primary outcome measure for the ensuing RCT
Week 30
Secondary Outcomes (5)
Attainment of normal menstrual cycle length (i.e. 21-35 days)
1 (baseline), week 10 (end of treatment) and week 30 (end of study)
Hormonal imbalances and irregular menses (commonly regarded at 6 cycles per annum or less)
1 (baseline), week 10 (end of treatment) and week 30 (end of study)
weight, body mass index (BMI), hirsutism, thinning hair
week 1 (baseline), week 10 (end of treatment) and week 30 (end of study)
Fasting Insulin and blood sugar levels
week 1 (baseline), week 10 (end of treatment) and week 30 (end of study)
Quality of Life
week 1 (baseline), week 10 (end of treatment) and week 30 (end of study)
Study Arms (2)
1
EXPERIMENTALReflexology
2
NO INTERVENTIONNo intervention
Interventions
Eligibility Criteria
You may qualify if:
- Women with PCOS
You may not qualify if:
- use of complimentary therapies within 6/12 prior to recruitment
- BMI \>35
- taken combined oral contraceptives, metformin, or cyclical progestogens within 3/12 prior to recruitment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Nottingham Hospitals
Nottingham, Nottingham, NG7 2UH, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dawn-Marie Walker, PhD
University of Nottingham
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 2, 2008
First Posted
September 3, 2008
Study Start
December 1, 2012
Primary Completion
November 1, 2013
Study Completion
December 1, 2013
Last Updated
December 4, 2012
Record last verified: 2012-12